ROSE2: Obicetrapib/ezetimibe combination further lowers LDL in statin-treated patients
In statin-treated patients with dyslipidemia, the combination of obicetrapib and ezetimibe further lowered LDL, according to the results of the phase 2 ROSE2 trial. As Healio previously reported, obicetrapib (NewAmsterdam Pharma), an investigational cholesteryl ester transfer protein (CETP) inhibitor, decreased LDL, non-HDL, lipoprotein(a) and apolipoprotein B and increased HDL at 8 weeks in
Newamsterdam Pharma Michaelh Davidson Richard Smith Byerik Swain Lipid Clinic At University Of Chicago Medicine National Lipid Association Scientific Sessions
Source: healio.com